A Multi-Center, Randomized, Double-Blind, Active-controlled, Phase 2, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease.
Latest Information Update: 04 Sep 2020
Price :
$35 *
At a glance
- Drugs Fexuprazan (Primary) ; Esomeprazole
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 20 Jun 2018 Status changed from recruiting to completed.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 14 Jun 2017 New trial record